We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
13.00 | 0.66% | 1,994.00 | 2,004.00 | 2,006.00 | 2,008.00 | 1,979.00 | 1,987.00 | 215,580 | 16:35:01 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 23.10 | 4.43B |
Hikma Pharmaceuticals PLC - Discretionary Share Award
LONDON, 17 April 2024: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the following conditional award under the Hikma Pharmaceuticals PLC 2023 Long Term Incentive Plan (the "LTIP") to Hafrun Fridriksdottir, a Person Discharging Managerial Responsibility ("PDMR") of the Company. No consideration was paid for the grant of the award.
The award under the LTIP was made on 16 April 2024 based on a price of £18.64 per Ordinary Share (being the average mid-market Ordinary Share price for the 5-working day period prior to 9 April 2024, in accordance with the LTIP rules) (the "LTIP Award"). The vesting of the LTIP Award is subject to the continued employment of the PDMR, malus and clawback provisions, and the satisfaction of performance conditions set by the Remuneration Committee of the Company. The LTIP Award will normally vest on the later of the third anniversary of the date of grant and the determination of the performance conditions. The LTIP Award is then subject to an additional two-year holding period.
This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||
a) |
Name |
Hafrun Fridriksdottir |
|
2 |
Reason for the notification |
||
a) |
Position/status |
PDMR |
|
b) |
Initial notification /Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
a) |
Name |
Hikma Pharmaceuticals PLC |
|
b) |
LEI |
549300BNS685UXH4JI75 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
a) |
Description of the financial instrument, type of instrument and identification code |
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
|
b) |
Nature of the transaction
|
Grant of award under the LTIP. |
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
Nil |
LTIP Award: 57,374 |
||
d) |
Aggregated information |
Price(s): Nil Volume(s): 57,374 |
|
e) |
Date of the transaction |
16 April 2024 |
|
f) |
Place of the transaction |
Outside a trading venue |
Helen Middlemist
Group Company Secretary
+44 (0) 20 7399 2760
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions